Member's news
National Ophthalmology Database Audit Annual Report finds significantly better outcomes for cataract surgery patients
The RCOphth has released its annual report for the National Ophthalmology Database (NOD) Audit 2018-2019. Since its inception, the NOD audit has been assuring high quality cataract surgical services for patients. The annual report finds a 40% overall reduction in the posterior capsule rupture (PCR) complication rates and a continuing decline in the number of
Statement on updated professional standards on refractive surgery
Remote consultations have been given additional impetus by the COVID emergency and are almost certainly one of the changes in practice that is here to stay. The advantages for the patient in terms of access are obvious, and video meeting platforms are now part of our daily lives. Video calls add emotional cues that are
Supporting ophthalmology trainees back into the training programme during the pandemic
As the COVID-19 pandemic continues, The Royal College of Ophthalmologists recognises the need to support a return to normal training and limit any further disruption. The Ophthalmologists in Training Group (OTG), working with the RCOphth, has produced a framework of recommendations, the Training Programme Recovery Recommendations, to help deal with this evolving and complex situation.
RCOphth responds to new framework for restarting National Institute of Health Research activities
The National Insitute of Health Research NIHR has set out a framework to guide the restarting of NIHR research activities which have been paused due to COVID-19. This framework has been developed in cooperation with Devolved Administrations who will produce aligned, but specific guidance for their area. Commenting on the new framework, RCOphth Academic Committee
Mitomycin Shortage Resolution
The UK has been experiencing a shortage of mitomycin 2mg, 10mg, 20mg vials for intravenous administration and 40mg for intravesical administration since late October 2019. Since the recall of Kyowa Kirin product in early November 2019 all Trusts have had to rely on unlicensed imports. Kyowa Kirin have withdrawn their marketing authorisation for Mitomycin-C and